JP2024524375A5 - - Google Patents
Info
- Publication number
- JP2024524375A5 JP2024524375A5 JP2023580472A JP2023580472A JP2024524375A5 JP 2024524375 A5 JP2024524375 A5 JP 2024524375A5 JP 2023580472 A JP2023580472 A JP 2023580472A JP 2023580472 A JP2023580472 A JP 2023580472A JP 2024524375 A5 JP2024524375 A5 JP 2024524375A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant
- kremen1
- nucleic acid
- acid molecule
- osteoporosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163218212P | 2021-07-02 | 2021-07-02 | |
| US63/218,212 | 2021-07-02 | ||
| PCT/US2022/035783 WO2023278741A1 (en) | 2021-07-02 | 2022-06-30 | Methods of treating decreased bone mineral density with kringle containing transmembrane protein 1 (kremen1) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524375A JP2024524375A (ja) | 2024-07-05 |
| JP2024524375A5 true JP2024524375A5 (https=) | 2025-06-23 |
Family
ID=82748403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580472A Pending JP2024524375A (ja) | 2021-07-02 | 2022-06-30 | クリングル含有膜貫通タンパク質１（ｋｒｅｍｅｎ１）阻害剤で骨ミネラル密度低下を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230021584A1 (https=) |
| EP (1) | EP4363585A1 (https=) |
| JP (1) | JP2024524375A (https=) |
| KR (1) | KR20240043752A (https=) |
| CN (1) | CN117836412A (https=) |
| AU (1) | AU2022300984A1 (https=) |
| CA (1) | CA3222830A1 (https=) |
| IL (1) | IL309385A (https=) |
| WO (1) | WO2023278741A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118298911B (zh) * | 2024-04-12 | 2024-11-22 | 中山大学孙逸仙纪念医院 | 一种多部位慢性疼痛潜在治疗靶点确定系统 |
-
2022
- 2022-06-30 CN CN202280057215.XA patent/CN117836412A/zh active Pending
- 2022-06-30 WO PCT/US2022/035783 patent/WO2023278741A1/en not_active Ceased
- 2022-06-30 JP JP2023580472A patent/JP2024524375A/ja active Pending
- 2022-06-30 US US17/855,053 patent/US20230021584A1/en active Pending
- 2022-06-30 IL IL309385A patent/IL309385A/en unknown
- 2022-06-30 KR KR1020247003956A patent/KR20240043752A/ko active Pending
- 2022-06-30 AU AU2022300984A patent/AU2022300984A1/en active Pending
- 2022-06-30 EP EP22748568.7A patent/EP4363585A1/en active Pending
- 2022-06-30 CA CA3222830A patent/CA3222830A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102639151B (zh) | 通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白（hbf/hbg）相关疾病 | |
| KR101770435B1 (ko) | 자연 안티센스 전사체가 아포리포단백질-ａ1로 억제에 의해 아포리포단백-ａ1 관련된 질환의 치료 | |
| JP6026482B2 (ja) | 腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療 | |
| RU2551234C2 (ru) | Лечение сиртуин 1 (sirt1)-связанных заболеваний путем ингибирования натурального антисмыслового транскрипта | |
| CN102341498B (zh) | 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病 | |
| JP6091752B2 (ja) | Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療 | |
| WO2016164463A1 (en) | Methods for reactivating genes on the inactive x chromosome | |
| JP2024524375A5 (https=) | ||
| CN104684927B (zh) | 用于治疗与herv-w包膜蛋白表达相关的疾病中的髓鞘再生阻断的化合物 | |
| JP2024528284A5 (https=) | ||
| Hu et al. | Impaired bone strength and bone microstructure in a novel early-onset osteoporotic rat model with a clinically relevant PLS3 mutation | |
| JP2009516710A (ja) | ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート | |
| JP2024524388A5 (https=) | ||
| US10449200B2 (en) | Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer | |
| CA2505842A1 (en) | Translational control by small, non-translatable rnas | |
| JP6407912B2 (ja) | ヘモグロビン（ｈｂｆ／ｈｂｇ）に対する天然アンチセンス転写物の抑制によるｈｂｆ／ｈｂｇ関連疾患の治療 | |
| CN114788866B (zh) | Mafg作为胆固醇稳态调控靶点的应用及其调控剂 | |
| KR101121987B1 (ko) | 파골세포 골흡수 억제 ｓｉＲＮＡ 발현 벡터 및 이를 이용한 유전자 치료제 | |
| Mitsutake et al. | BRAF mediates RET/PTC-induced MAPK activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis | |
| JP2024524554A5 (https=) | ||
| CA3202382A1 (en) | Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same | |
| JP2024524526A5 (https=) | ||
| US20050261226A1 (en) | Methods and compositions for the treatment of cancer with oligonucleotides directed against Egr-1 | |
| CN114788865A (zh) | miR-378作为胆固醇稳态调控靶点的应用 | |
| Garin et al. | 6A3‐5/Osa2 is an Early Activated Gene Implicated in the Control of Vascular Smooth Muscle Cell Functions |